Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective study

Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective study

Abstract Background Head and neck squamous cell carcinoma (HNSCC) is a very common type of head and neck cancer, and the 5-year overall survival (OS) rate is only 50%. Inhibitors targeting the programmed death 1 (PD-1) pathway have gained widespread clinical adoption. However, the relationship betwe...

Full description

Saved in:
Bibliographic Details
Main Authors: Haifeng Liang, Wenting Liang, Jiawang Tian, Shibei Zheng, Yangzhou Su, Piao Huang, Renhui Chen, Zhong Guan, Qian Cai
Format: Article
Language:English
Published: Springer 2025-02-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Head and neck squamous cell carcinoma
Immunotherapy
PD-1 inhibitor
Online Access:https://doi.org/10.1007/s00262-025-03953-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-03953-0

Similar Items